Zydus Lifesciences has received final U.S. FDA approval for its Indocyanine Green injection. The approval includes a Competitive Generic Therapy designation, which may allow the company to be the sole supplier of the drug in the U.S. market for six months. This product competes in a market segment valued at approximately $125.8 million, helping the company expand its portfolio of complex injectable medicines.
Zydus Lifesciences announced on Tuesday that it has received final approval from the U.S. Food and Drug Administration (USFDA) for its Indocyanine Green for Injection, a product used in surgical imaging. This approval comes with a Competitive Generic Therapy (CGT) designation, a regulatory status that rewards companies for bringing competition to the market for products with few or no generic alternatives. This status may provide Zydus with a 180-day window of market exclusivity, allowing it to be the only company selling this generic version in the U.S. once commercial sales begin.
Impact of the Market Exclusivity
The 180-day exclusivity period is a significant advantage for Zydus Lifesciences as it prevents other manufacturers from launching their generic versions during this timeframe. This allows the company to capture a larger share of the market early on without direct generic competition. According to data from IQVIA for the period ending June 2026, the reference product for this injection recorded U.S. sales of approximately $125.8 million, with an annual volume of about 0.64 million units. Capturing this market segment aligns with the company’s strategy of expanding its reach in high-value, complex injectable products.
Manufacturing and Operational Scope
The drug will be produced at the company’s manufacturing plant in Jarod, Gujarat, which has already received approval from the U.S. drug regulator. The product will be distributed in the American market through the company's subsidiary, Zydus Pharmaceuticals (USA) Inc. This addition marks a continuation of the company's efforts to increase its footprint in the U.S. market. As of June 30, 2026, Zydus had secured a total of 445 product approvals and filed 513 abbreviated new drug applications (ANDAs) with the USFDA.
Investor Context and Next Steps
Indocyanine Green is a specialized imaging agent used to visualize blood vessels and tissue during delicate surgical procedures, such as organ transplants and vascular surgeries. While this approval is a positive development for the company’s portfolio, investors should monitor the company’s ability to scale manufacturing and navigate any potential supply chain challenges to fully utilize the 180-day exclusivity window. The actual financial contribution from this product will depend on the successful commercial launch and the company’s ability to maintain its pricing and market share against the original branded product. Shares of Zydus Lifesciences reacted to the announcement by closing 0.80% higher at ₹1,130.00 on the NSE on Tuesday.